The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

Louvain-La-Neuve, Belgium, and Paris, France, 7 February 2025 - Framatome, an international leader in nuclear energy committed to developi ...

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Louvain-La-Neuve, Belgium, and Paris, France, 7 February 2025 - Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA ...

On Wednesday, officials said the remains of all 67 victims from a midair collision involving American Airlines Flight 5342 ...

Rheumatoid arthritis (RA) is an inflammatory arthritis characterized by chronic joint inflammation, cartilage degradation, and bone erosion. ELK3 is a ...

We think Kao is in sound financial shape given its low leverage and strong cash reserve. The company is in net cash position with its debt/equity ratio being notably lower than international wide-moat ...

The HUMANOID Center at UC San Diego is pioneering organoid research aimed at improving the reliability and reproducibility of ...